France's hopes of tightening the prescription guidelines for birth-control pills that are linked with a relatively higher risk of blood clots received a blow after the European Medicines Agency (EMA) rejected its request by stating that the benefits of such pills outweigh the risks.
A panel reviewed the evidence and concluded that the "benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks," the EU watchdog said, using the medical term for contraceptive pills.
"There is no reason for women who have been using CHCs without any problem to stop taking them on the basis of this review."
These contain synthetic versions of the female progestogen, which the makers say avoid some of the side-effects of older formulations.
A Danish study in 2011 found that women who used later generations of the pill ran twice the risk of developing blood clots, known as venous thromboembolism (VTE), compared to those who used older-generation drugs.
Compared with non-users of the Pill, the risk of a clot was three to six times higher. A VTE can be dangerous as clots formed in the veins can break up and be transported to the heart or lungs.
In absolute terms, though, the risk is low, experts have said.
In its review, the EMA's Pharmacovigilance Risk Assessment Committee found that the risk of VTEs with all contraceptives "is small," the agency said.
"There are small differences between the CHCs depending on the type of progestogen they contain," it added.
The EMA said it recommended updating the product information leaflet for birth control pills "to help women make informed decisions about their choice of contraception."
It also recalled advice to doctors to make regular assessments about the risk of blood clots to any patient who is taking contraceptive pills.
Risk factors include smoking, migraines, being overweight and increasing signs of ageing, the agency noted.
France had wanted the EMA to recommend that doctors no longer prescribe later-generation pills as a first option.
The health ministry also dropped the two later generations of the pill from the list of medications that are reimbursed under France's national health insurance programme.